Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit

Anthony D. Dorr; Charu Chopra; Tanya I. Coulter; John Dempster; Magdalena Dziadzio; Tariq el-Shanawany; Tomaz Garcez; Mark Gompels; Richard Herriot; Rashmi Jain; Marcel Levi; Lorena Lorenzo; Inas Makki; Elizabeth Mapazire; Sai H. K. Murng; Sadia Noorani; Sinisa Savic; Cathal L. Steele; Christine Symons; Michael Tarzi; Patrick F. K. Yong; Sorena Kiani-Alikhan

doi:https://doi.org/10.1111/all.15620

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit

Anthony D. Dorr, Charu Chopra, Tanya I. Coulter, John Dempster, Magdalena Dziadzio, Tariq el-Shanawany, Tomaz Garcez, Mark Gompels, Richard Herriot, Rashmi Jain, Marcel Levi, Lorena Lorenzo, Inas Makki, Elizabeth Mapazire, Sai H. K. Murng, Sadia Noorani, Sinisa Savic, Cathal L. Steele, Christine Symons, Michael TarziPatrick F. K. Yong, Sorena Kiani-Alikhan

Research output: Contribution to journal › Comment/Letter to the editor › Academic

1 Citation (Scopus)

Original language	English
Pages (from-to)	1369-1371
Number of pages	3
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	78
Issue number	5
Early online date	2022
DOIs	https://doi.org/10.1111/all.15620
Publication status	Published - May 2023

Access to Document

https://doi.org/10.1111/all.15620

Cite this

Dorr, A. D., Chopra, C., Coulter, T. I., Dempster, J., Dziadzio, M., el-Shanawany, T., Garcez, T., Gompels, M., Herriot, R., Jain, R., Levi, M., Lorenzo, L., Makki, I., Mapazire, E., Murng, S. H. K., Noorani, S., Savic, S., Steele, C. L., Symons, C., ... Kiani-Alikhan, S. (2023). Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit. Allergy: European Journal of Allergy and Clinical Immunology, 78(5), 1369-1371. https://doi.org/10.1111/all.15620

@article{1c25c0593bd04f2fa3fff503fa4f7527,

title = "Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit",

author = "Dorr, {Anthony D.} and Charu Chopra and Coulter, {Tanya I.} and John Dempster and Magdalena Dziadzio and Tariq el-Shanawany and Tomaz Garcez and Mark Gompels and Richard Herriot and Rashmi Jain and Marcel Levi and Lorena Lorenzo and Inas Makki and Elizabeth Mapazire and Murng, {Sai H. K.} and Sadia Noorani and Sinisa Savic and Steele, {Cathal L.} and Christine Symons and Michael Tarzi and Yong, {Patrick F. K.} and Sorena Kiani-Alikhan",

note = "Funding Information: AD – Has received honoraria and support for attending scientific meetings from Takeda. JD – Has received honoraria from BioCryst, CSL Behring, Pharming, Takeda (previously Shire) for advisory board and speaking services. JD has also received reasonable expenses to attend meetings and conferences from CSL Behring, and Takeda (previously Shire). MD – Has received support for attending scientific meetings from CSL and Takeda. TE – Has received educational support, speaker fees and/or advisory board fees from: Allergy Therapeutics, CSL, Novartis, Takeda, Thermo Fisher, Viatris. TG – Is the past Chair of NHS England Clinical Reference Group for immunology and allergy and has received honoraria from BioCryst, CSL Behring, Octapharma, Pharming, Takeda (previously Shire) for advisory board and speaking services. TG has also received reasonable expenses to attend meetings and conferences from BioCryst, CSL Behring, Pharming, Takeda (previously Shire). RJ – Has received support for attending Educational Events from CSL and Takeda. LL – Has received educational grants from Biotest and CSL, advisory and consulting activity with Pharming and speaker's fee from Takeda and Biocryst. SS – Has received educational support speaker fees and/or advisory board fees from: Takeda, CSL, Novartis, BioCryst, KalVista. CS – Has received speaker fees, honoraria and/or support for attending meetings from Biocryst, CSL Behring, Pharming and Takeda. PY – Has received consulting fees, honoraria and/or support for attending meetings from Biocryst, CSL Behring, Pharming and Takeda. SK – Has been chief and/or principal investigator for studies and in receipt of honorarium for consulting work and advisory boards organized by; Shire/Takeda, CSL Behring, Biocryst, Biotest, KalVista, Pharvaris, X4 Pharmaceuticals, Ionis Pharmaceuticals. CC, TC, MG, RH, ML, IM, EM, SM, SN, CLS, MT – No conflicts to declare.",

year = "2023",

month = may,

doi = "https://doi.org/10.1111/all.15620",

language = "English",

volume = "78",

pages = "1369--1371",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell",

number = "5",

}

Dorr, AD, Chopra, C, Coulter, TI, Dempster, J, Dziadzio, M, el-Shanawany, T, Garcez, T, Gompels, M, Herriot, R, Jain, R, Levi, M, Lorenzo, L, Makki, I, Mapazire, E, Murng, SHK, Noorani, S, Savic, S, Steele, CL, Symons, C, Tarzi, M, Yong, PFK & Kiani-Alikhan, S 2023, 'Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit', Allergy: European Journal of Allergy and Clinical Immunology, vol. 78, no. 5, pp. 1369-1371. https://doi.org/10.1111/all.15620

TY - JOUR

T1 - Lanadelumab for the prevention of hereditary angioedema attacks

T2 - A real-world UK audit

AU - Dorr, Anthony D.

AU - Chopra, Charu

AU - Coulter, Tanya I.

AU - Dempster, John

AU - Dziadzio, Magdalena

AU - el-Shanawany, Tariq

AU - Garcez, Tomaz

AU - Gompels, Mark

AU - Herriot, Richard

AU - Jain, Rashmi

AU - Levi, Marcel

AU - Lorenzo, Lorena

AU - Makki, Inas

AU - Mapazire, Elizabeth

AU - Murng, Sai H. K.

AU - Noorani, Sadia

AU - Savic, Sinisa

AU - Steele, Cathal L.

AU - Symons, Christine

AU - Tarzi, Michael

AU - Yong, Patrick F. K.

AU - Kiani-Alikhan, Sorena

N1 - Funding Information: AD – Has received honoraria and support for attending scientific meetings from Takeda. JD – Has received honoraria from BioCryst, CSL Behring, Pharming, Takeda (previously Shire) for advisory board and speaking services. JD has also received reasonable expenses to attend meetings and conferences from CSL Behring, and Takeda (previously Shire). MD – Has received support for attending scientific meetings from CSL and Takeda. TE – Has received educational support, speaker fees and/or advisory board fees from: Allergy Therapeutics, CSL, Novartis, Takeda, Thermo Fisher, Viatris. TG – Is the past Chair of NHS England Clinical Reference Group for immunology and allergy and has received honoraria from BioCryst, CSL Behring, Octapharma, Pharming, Takeda (previously Shire) for advisory board and speaking services. TG has also received reasonable expenses to attend meetings and conferences from BioCryst, CSL Behring, Pharming, Takeda (previously Shire). RJ – Has received support for attending Educational Events from CSL and Takeda. LL – Has received educational grants from Biotest and CSL, advisory and consulting activity with Pharming and speaker's fee from Takeda and Biocryst. SS – Has received educational support speaker fees and/or advisory board fees from: Takeda, CSL, Novartis, BioCryst, KalVista. CS – Has received speaker fees, honoraria and/or support for attending meetings from Biocryst, CSL Behring, Pharming and Takeda. PY – Has received consulting fees, honoraria and/or support for attending meetings from Biocryst, CSL Behring, Pharming and Takeda. SK – Has been chief and/or principal investigator for studies and in receipt of honorarium for consulting work and advisory boards organized by; Shire/Takeda, CSL Behring, Biocryst, Biotest, KalVista, Pharvaris, X4 Pharmaceuticals, Ionis Pharmaceuticals. CC, TC, MG, RH, ML, IM, EM, SM, SN, CLS, MT – No conflicts to declare.

PY - 2023/5

Y1 - 2023/5

UR - http://www.scopus.com/inward/record.url?scp=85144269333&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/all.15620

DO - https://doi.org/10.1111/all.15620

M3 - Comment/Letter to the editor

C2 - 36510404

SN - 0105-4538

VL - 78

SP - 1369

EP - 1371

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 5

ER -

Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit

Access to Document

Other files and links

Cite this